New pill aims to relieve long COVID misery
NCT ID NCT05999435
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tested an oral medication called LAU-7b in 272 adults with Long COVID and moderate to severe symptoms. The drug is designed to reduce inflammation and fight viruses. The main goal was to see if it improves physical health and daily function after 12 weeks compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIUSS du Saguenay-Lac-St-Jean - Hôpital Chicoutimi
Chicoutimi, Quebec, G7H 5H6, Canada
-
Centre Hospitalier de l'Université de Sherbrooke
Sherbrooke, Quebec, J1H 5N4, Canada
-
Diex Recherche Québec Inc.
Québec, Quebec, G1V 4T3, Canada
-
Institut de Recherches Cliniques de Montréal
Montreal, Quebec, H2W 1R7, Canada
-
Montreal General Hospital
Montreal, Quebec, H3G 1A4, Canada
Conditions
Explore the condition pages connected to this study.